MFine in JV with LifeCell Diagnostics
Expands diagnostics footprint
Healthcare services platform MFine in a joint venture with LifeCell Diagnostics, announced the expansion of its offline footprint with the opening of the 100th Patient Service Center (PSC). The companies in July this year announced a joint venture LifeWell, including an $80 million fundraising from OrbiMed Asia. The PSC has facilities for sample collection for blood tests along with assisted teleconsultations, booking for imaging/radiology tests at neighbourhood centres and home delivery of medicines.
The company seeks to rapidly expand its network from already established 25+ MFine branded pathology labs and 100+ experience centres across 15+ cities to a network of 50+ labs and 500+ patient service centres across 30+ cities covering pathology, radiology, and genomics by March 2023. To execute on this the company shall support the organic building up of a nationwide lab network by also onboarding existing high-quality radiology and pathology lab assets through a roll-up process. The company has already completed the integration of Mumbai-based Health Solutions Pathology.
With this rapid expansion, MFine will be providing a seamless omnichannel experience of consuming healthcare services. The high-density network enables fast, accurate and high-quality diagnostics services which can be availed from either at-home or at-centre.
Mayur Abhaya, MD & CEO, LifeCell International said, “LifeCell Diagnostics, already a market leader in providing advanced genetic and genomic testing services for prenatal and newborns, has now expanded its menu to 3200+ tests spread across categories including infections, oncology, etc apart from routine investigations, through our network of NABL & CAP accredited labs. The collaboration with MFine will help expand easier and faster access to these tests.”
Prasad Kompalli, Cofounder and CEO, MFine, said, “MFine is moving ahead towards our vision of on-demand healthcare services and bridging the experience gaps between digital and physical channels. We would continue to build the MFine platform with tools and services and offer an integrated care delivery experience for our users. In this joint venture, we have brought together the complementary capabilities of teams building a vast network of state-of-the-art diagnostics centres and a market-leading digital health platform. You will see us bring innovations and experiences of unprecedented quality and convenience in the coming days to both D2C and Corporate customers.”